Latest Watson Stories

IBM Cited As a Leader in Business Intelligence Services by Independent Research Firm

2012-11-08 08:41:11

ARMONK, N.Y., Nov. 8, 2012 /PRNewswire/ -- IBM (NYSE: IBM) today announced that Forrester Research, Inc. has recognized IBM as a market leader in business intelligence (BI) services according to the October 2012 report, The Forrester Wave(TM): Business Intelligence Services Providers, Q4 2012(1). The report, which evaluates the leading BI providers by strategy and technology expertise, cites IBM as leading the market in both areas. (Logo:...

Watson to Present at the 2012 Annual Credit Suisse Healthcare Conference

2012-11-06 08:29:27

PARSIPPANY, N.J., Nov. 6, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2012 Annual Credit Suisse Health Care Conference on Wednesday, November 14, 2012 at 11:30 am MST (1:30 pm EST) at the Arizona Biltmore Hotel in Phoenix. The presentation will be webcast live and can be...

Watson Announces Global Generics Management Team

2012-10-31 19:21:47

PARSIPPANY, N.J., Oct. 31, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced the Global Generics management team, following the announcement of the completion of the acquisition of the Actavis Group for EUR 4.25 billion. The combination creates the world's third largest generic pharmaceutical company, with anticipated pro forma combined 2012 revenues in excess of $8 billion. "Since the announcement of our intention to acquire Actavis in April 2012, we...

Watson Announces New Name -- Actavis -- for Global Operations

2012-10-31 19:21:44

PARSIPPANY, N.J., Oct. 31, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it will adopt a new global name - Actavis - effective in 2013. The Company said it will initiate a multi-year rebranding campaign for its facilities, operations and commercial presence, and will transition to trading under a new symbol on the New York Stock Exchange in 2013. "When we announced the proposed acquisition of Actavis in April 2012, we immediately instituted...

Watson Completes Actavis Acquisition

2012-10-31 19:21:40

PARSIPPANY, N.J., Oct. 31, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has completed the acquisition of the Actavis Group for EUR 4.25 billion. The combination creates the world's third largest generic pharmaceutical company, with anticipated pro forma combined 2012 revenues in excess of $8 billion. Watson funded the transaction through a combination of $1.8 billion in term loan borrowings and the issuance of $3.9 billion in senior...

Cleveland Clinic and IBM Work to Advance Watson's Use in the Medical Training Field

2012-10-29 23:20:23

CLEVELAND, Oct. 30, 2012 /PRNewswire/ -- Cleveland Clinic and IBM (NYSE: IBM) announced today the formation of a collaboration to advance Watson's use in the medical training field. The IBM team of researchers that created Watson will work with Cleveland Clinic clinicians, faculty and medical students to enhance the capabilities of Watson's Deep Question Answering technology for the area of medicine. (Photo - http://photos.prnewswire.com/prnh/20121030/NY02420-a)(Photo -...

Watson Announces Sale of Rugby OTC Product Trademark and Assets to Major Pharmaceuticals, a division of The Harvard Drug Group, LLC

2012-10-29 11:25:26

PARSIPPANY, N.J., Oct. 29, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that it has sold its Rugby over-the-counter ("OTC") pharmaceutical products and trademarks to The Harvard Drug Group, LLC, a leading distributor and provider of private label OTCs and generic prescription products, for approximately $117 million. The transaction received clearance from the U.S. Federal Trade Commission on October 19,...

Watson Receives FDA Approval for Generic Actos®

2012-10-26 15:22:14

PARSIPPANY, N.J., Oct. 26, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that Watson has launched a generic version of Actos® (Pioglitazone Hydrochloride 15mg, 30mg and 45mg tablets) after receiving final approval today from the U.S. Food and Drug Administration (FDA). Watson began shipping the product immediately. On August 15, 2012, Watson announced that it had filed suit against the FDA challenging the Agency's decision regarding Watson's...

Watson Confirms FDA Denies Appeal Related to Prochieve® NDA for the Prevention of Preterm Birth

2012-10-26 07:23:49

PARSIPPANY, N.J., Oct. 26, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that the U.S. Food and Drug Administration (FDA) denied the Company's Formal Dispute Resolution Request (FDRR) related to its pending New Drug Application (NDA) for Prochieve for the prevention of preterm birth in women with a short cervical length. The Company said it intends to review possible options related to the continued pursuit of the NDA. Watson filed its FDRR in August...

IBM Announces Student Winners of Watson Case Competition from Cornell University

2012-10-23 15:26:07

LAS VEGAS, Oct. 23, 2012 /PRNewswire/ -- Cornell University and IBM (NYSE: IBM) today announced the winners of the second Watson Academic Case Competition. The contest helps students build skills in analytics, big data and cognitive computing by identifying new ideas for applying IBM Watson to solve societal and business challenges. (Photo: http://photos.prnewswire.com/prnh/20121023/NY97681-a )(Photo: http://photos.prnewswire.com/prnh/20121023/NY97681-b )(Logo:...